---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-096163"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:46:07.239386+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Nkarta Q2 net loss $25M; cash $426.7M; plans Ntrust-2 trial by year-end

## Summary
- Net loss of $25.0M ($0.34 per share) for Q2 2024; R&D expenses $23.1M, G&A $7.6M.
- Cash, equivalents and investments of $426.7M at June 30, 2024; expected to fund operations into late 2027.
- FDA clearance received for second IND for NKX019 in autoimmune disease; Ntrust-2 enrollment expected by year-end 2024.
- Preliminary data from Ntrust-1 and Ntrust-2 planned for 2025; IST in SLE/LN initiated at Columbia University.
- Nadir Mahmood joined as President; David Shook promoted to CMO, Head of R&D in July 2024.

## SEC filing metadata
- accession: 0000950170-24-096163
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017024096163/0000950170-24-096163-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017024096163/nktx-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-096163
- JSON: https://secwatch.observer/filing/0000950170-24-096163.json
- Plain text: https://secwatch.observer/filing/0000950170-24-096163.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.